Taken together these data show that sapanisertib plus serabelisib, with the optional addition of ISD, represents a comprehensive multi-nodal approach for the effective inhibition of PI3K/AKT/mTOR signalling in tumours in vivo (Supplementary Fig. S5e). Here, AKT1 is linked to neoplasm.